WO2026029097A1 - 新規幹細胞の分離培養方法、単離された新規幹細胞、間葉系幹細胞バンク、および、間葉系幹細胞情報提供方法 - Google Patents
新規幹細胞の分離培養方法、単離された新規幹細胞、間葉系幹細胞バンク、および、間葉系幹細胞情報提供方法Info
- Publication number
- WO2026029097A1 WO2026029097A1 PCT/JP2025/026989 JP2025026989W WO2026029097A1 WO 2026029097 A1 WO2026029097 A1 WO 2026029097A1 JP 2025026989 W JP2025026989 W JP 2025026989W WO 2026029097 A1 WO2026029097 A1 WO 2026029097A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hla
- mesenchymal stem
- locus
- stem cells
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Definitions
- the disclosures in this application relate to a novel method for isolating and culturing stem cells, the isolated novel stem cells, a mesenchymal stem cell bank, and a method for providing information on mesenchymal stem cells.
- MSCs Mesenchymal stem cells
- Mesenchymal stem cells are one type of tissue stem cell present in the adult human body. MSCs are found in various locations, including bone marrow, fat, and the dermis of the skin. The properties of MSCs vary slightly depending on the location. MSCs have the ability to differentiate into tissues (bone, cartilage, blood vessels, muscle, fat, fibroblasts, etc.) classified as mesoderm, which is formed between the ectoderm (epidermis and its derived tissues and nervous system) and the endoderm (digestive tract and its derived tissues) in embryological classification, but can also transdifferentiate into ectoderm (neuronal cells) and endoderm (liver cells).
- tissues bone, cartilage, blood vessels, muscle, fat, fibroblasts, etc.
- mesoderm which is formed between the ectoderm (epidermis and its derived tissues and nervous system) and the endoderm (digestive tract and its derived tissues)
- MSCs' interferon- ⁇ responsiveness and ability to produce nitric oxide play important roles, and components of the proteins (secretome) secreted by MSCs, such as chemokines, have an inhibitory effect on the immunoglobulin (antibody) production of plasma cells. As a result, they are thought to have immune-regulating capabilities, and even though they are derived from other people, they are said to have a weaker rejection reaction than other cells.
- MSCs are known to be derived from a patient's own adipose tissue, bone marrow, and umbilical cord blood. While using autologous cells is desirable to reduce the risk of rejection, there is the issue of invasiveness during collection. Bone marrow collection is particularly invasive compared to fat.
- umbilical cord blood contains many immature, rapidly proliferating cells. A fetus's immunity (both innate and adaptive) is immature at birth, and it is said that innate immunity begins to develop around 18 months of age. Umbilical cord blood collected immediately after birth is fetal blood, but because the fetus receives antibodies from the mother through the placenta, antibodies are also present in umbilical cord blood.
- Non-Patent Document 1 describes that mesenchymal stem cells can be obtained from the chorionic plate plus amnion (CP), chorionic villi (CV), and decidua (DB) tissues of the placenta in the late stages of pregnancy.
- CP chorionic plate plus amnion
- CV chorionic villi
- DB decidua
- Non-Patent Document 1 describes that MSCs can be obtained from placental tissue.
- HLA Human Leukocyte Antigen
- Known types of HLA include HLA-Class I (ABC) and HLA-G.
- HLA-ABC is a transmembrane protein expressed in most nucleated cells and platelets, and is known to be an important immune mechanism involved in distinguishing between self and non-self. In other words, strong expression of HLA-ABC increases the risk of rejection during MSC transplantation. Therefore, it is preferable that MSCs used for transplantation have low HLA-ABC expression.
- HLA-G binds to the NK cell inhibitory receptor KIR2DL4, helping to avoid attacks from NK cells. In other words, high expression of HLA-G is known to promote immune tolerance.
- HLA-ABC low expression of HLA-ABC, which is involved in distinguishing between self and non-self, and high expression of HLA-G are preferable.
- Non-Patent Document 1 the HLA-ABC described in Non-Patent Document 1 is positive and HLA-G is negative, which is the exact opposite of the characteristics required for MSCs used in regenerative medicine. Therefore, while it would be desirable to obtain placenta-derived MSCs that are HLA-ABC negative and HLA-G positive, MSCs with such characteristics have not yet been obtained, and no method for isolating and culturing them from placental tissue is known. Furthermore, no cell banks using MSCs with the above characteristics, nor methods for providing information on MSCs stored in cell banks, are known.
- the purpose of the disclosure in this application is to provide a novel method for isolating and culturing stem cells, and novel isolated stem cells; more specifically, to provide MSCs isolated from HLA-ABC-negative and HLA-G-positive placens, a method for isolating and culturing mesenchymal stem cells from placens, a method for purifying and concentrating MSCs having the characteristics disclosed in this application from cells cultured by the isolation and culture method, and a method for isolating MSCs having the characteristics disclosed in this application. Furthermore, the purpose of the disclosure in this application is to provide a cell bank using MSCs having the above-mentioned characteristics, and a method for providing information on MSCs stored in a cell bank.
- the disclosure of this application relates to the following: mesenchymal stem cells isolated from placenta, a method for isolating and culturing mesenchymal stem cells, a method for purifying and concentrating mesenchymal stem cells, a method for isolating mesenchymal stem cells, a mesenchymal stem cell bank, and a method for providing information on mesenchymal stem cells.
- mesenchymal stem cells isolated from a placenta comprising: HLA-ABC negative and HLA-G positive mesenchymal stem cells.
- the mesenchymal stem cells according to (1) above wherein the mesenchymal stem cells are isolated from placental tissue excluding the amniotic membrane.
- the mesenchymal stem cells according to (1) above wherein the mesenchymal stem cells are cultured using a serum-free medium.
- a method for isolating and culturing HLA-ABC-negative and HLA-G-positive mesenchymal stem cells from a placenta comprising: an enzyme treatment step of shredding and enzymatically treating placental tissue collected from the placenta; a first culture step of culturing the placenta tissue-derived cells obtained by the enzyme treatment in a serum-free medium; a second culture step of selecting mesenchymal stem cells from the cells cultured in the first culture step and culturing the selected mesenchymal stem cells using a serum-free medium; A method for isolating and culturing a plant.
- a method for purifying and concentrating mesenchymal stem cells that are HLA-ABC negative and HLA-G positive comprising:
- the mesenchymal stem cells cultured by the isolation and culture method according to any one of (6) to (8) above are A purification and concentration method comprising a selection step of selecting mesenchymal stem cells negative for HLA-ABC using an HLA-ABC antibody, and selecting mesenchymal stem cells positive for a mesenchymal stem cell marker using a mesenchymal stem cell marker antibody.
- a method for isolating mesenchymal stem cells that are HLA-ABC negative and HLA-G positive comprising: An isolation method comprising the step of isolating the mesenchymal stem cells after carrying out the purification and concentration method described in (9) above.
- a mesenchymal stem cell bank comprising the mesenchymal stem cells according to any one of (1) to (5) above, The mesenchymal stem cell bank includes: A mesenchymal stem cell bank comprising two or more types of mesenchymal stem cells that differ in at least one of HLA typing, HLA-A locus, HLA-B locus, and HLA-DR locus.
- the mesenchymal stem cell bank includes: At least one type selected from the group consisting of A*24:02, A*02:01, A*11:01, A*26:01, A*33:03, and A*31:01, which are typings of the HLA-A locus; At least one selected from the group consisting of HLA-B locus typing B*52:01, B*54:01, B*51:01, B*40:01, B*40:02, B*46:01, B*44:03, B*15:01 and B*07:02, and at least one selected from the group consisting of HLA-DR locus typing DRB1*04:05, DRB1*09:01, DRB1*15:02, DRB1*08:03, DRB1*13:02, DRB1*14:03 and DRB1*01:01;
- mesenchymal stem cells that are HLA-ABC negative and HLA-G positive can be obtained.
- FIG. 1 is a schematic diagram of the placenta.
- 2A is a photograph substituted for a drawing, showing a dish on day 5 after the start of cell culture in the isolation culture of Example 1.
- the scale bar is 200 ⁇ m.
- FIG. 2B is a photograph in place of a drawing, showing a phase contrast image and an immunostained photograph of cells on the 14th day of the isolation culture in Example 1.
- 3 is a photograph in place of a drawing, showing a phase contrast image and an immunostained photograph of MSCs after the second culture step in Example 1.
- the scale bar is 200 ⁇ m in both cases.
- FIG. 4 is a photograph in place of a drawing, and is a phase contrast image of MSCs after the second culture step in Example 1 and an immunostained photograph using an antibody different from that in Figure 3.
- the scale bar is 200 ⁇ m in both cases.
- FIG. 5 is a graph showing the results of FCM analysis of cells on day 14 of culture after the second culture step in Example 1.
- FIG. 6 is a graph showing the results of FCM analysis of cells on the 14th day of culture after the second culture step in Example 1 (labeled antibodies different from those in FIG. 5 ).
- FIG. 7 is a graph showing the results of FCM analysis after carrying out the purification and concentration method of Example 2.
- FIG. 8 is a photograph in place of a drawing, showing a phase contrast image and an immunostained photograph of the cells isolated and cultured in Comparative Example 1.
- the scale bar is 200 ⁇ m in both cases.
- FIG. 9 is a graph showing the results of FCM analysis of the cells isolated and cultured in Comparative Example 1.
- FIG. 10 is a graph showing the results of FCM analysis of the cells isolated and cultured in Comparative Example 2.
- 11 is a photograph in place of a drawing, showing a phase contrast image and an immunostained photograph of MSCs cultured for 5 passages in Example 3.
- the scale bar is 100 ⁇ m in both cases.
- FIG. 12 is a graph showing the results of FCM analysis of MSCs cultured for 5 passages in Example 3.
- mesenchymal stem cells isolated from the placenta may also be referred to simply as "MSCs"
- MSCs mesenchymal stem cells isolated from the placenta
- isolation and culturing method the method for isolating and culturing mesenchymal stem cells
- purifying and concentrating mesenchymal stem cells hereinafter, sometimes simply referred to as the "purification and concentration method”
- isolating mesenchymal stem cells hereinafter, sometimes simply referred to as the "isolation method” disclosed in this application.
- a numerical range expressed using “ ⁇ ” means a range that includes the numerical values written before and after “ ⁇ ” as the lower and upper limits
- Numerical values, numerical ranges, and qualitative expressions indicate numerical values, numerical ranges, and properties that include errors generally accepted in the technical field.
- MSCs are cells isolated from the placenta, are HLA-ABC negative and HLA-G positive, and express mesenchymal stem cell markers (hereinafter referred to as "MSC markers").
- FIG 1 shows an overview of the placenta. From the fetal side, the placenta is composed of the amnion, the chorionic hair growth portion (chorion), and the decidua basalis (decidua).
- the decidua is a tissue that has transformed from endometrium, and therefore contains many maternal cells.
- MSCs according to embodiments are relatively abundant on the chorionic side of the decidua and in the chorion, but are also present throughout the chorion. Therefore, MSCs according to embodiments are isolated from placental tissue excluding the amnion. Of the placental tissues excluding the amnion, the chorion and decidua on the decidua side are preferred.
- the placenta is said to be complete by 15 to 16 weeks of pregnancy. Therefore, the placenta used in this application includes placentas from 16 weeks of pregnancy or later, and from the standpoint of ease of acquisition, placentas from 28 weeks of late pregnancy to full term are included.
- HLA-ABC is known to be an important immune mechanism involved in distinguishing between self and non-self. Therefore, strong expression of HLA-ABC increases the risk of rejection during MSC transplantation. Therefore, it is preferable that the MSCs disclosed in this application have low HLA-ABC expression.
- positive means that a higher signal is detected using an analytical method such as flow cytometry, which utilizes an antigen-antibody reaction, compared to a negative control reaction using negative control cells that do not express the antigen or an antibody that does not react with the antigen.
- negative means that a signal that is equal to or lower than a negative control reaction using negative control cells that do not express the antigen or an antibody that does not react with the antigen is detected.
- the expression level is not zero as long as it is within the meaning of "negative” described above. In other words, some expression is not a problem, but zero expression is preferable.
- HLA-G high expression of HLA-G is known to promote immune tolerance. Therefore, when using MSCs for regenerative medicine, it is considered preferable to have low expression of HLA-ABC, which is involved in distinguishing between self and non-self, and high expression of HLA-G. For this reason, the MSCs disclosed in this application are preferably HLA-ABC negative and HLA-G positive.
- MSCs express MSC markers.
- MSC markers include, but are not limited to, CD29, CD71, CD90, and CD105.
- cells expressing mesenchymal stem cell markers can also be referred to as MSCs.
- MSCs Diseases that can be expected to be treated when MSCs are transplanted for therapeutic purposes include, but are not limited to, IgA nephropathy, arthritis, myocardial infarction, diabetic foot ulcers, acute graft-versus-host disease, brain injury, spinal cord injury and associated neurological symptoms and functional disorders, complex anal fistulas in Crohn's disease patients, acute respiratory distress syndrome due to pneumonia, hypophosphatasia, knee osteoarthritis, non-infectious pulmonary complications after hematopoietic stem cell transplantation, meniscus injury, and Duchenne muscular dystrophy. Transplantation of MSCs for therapeutic purposes is not limited to humans. Throughout this specification, the term "MSCs" refers to human MSCs as well as MSCs obtained from mammals such as pets such as dogs, cats, and mice; and livestock such as cows, horses, goats, and sheep.
- the MSC disclosed in this application has the following advantages. (1) MSCs are considered to have a low risk of rejection by the immune system, but the MSCs disclosed in this application have low (negative) expression of HLA-ABC, which is involved in the discrimination between self and non-self, and high (positive) expression of HLA-G, which promotes immune tolerance. Therefore, they are expected to be used in regenerative medicine, particularly in transplantation of MSCs from other people (allotransplantation). (2) As shown in the Examples below, the isolated MSCs disclosed in the present application maintain their characteristics of low HLA-ABC expression (negative) and high HLA-G expression (positive) even after repeated subculture. Therefore, MSCs with the same properties can be stably provided.
- Isolated MSCs can be cryopreserved. Therefore, by storing isolated MSCs, they can be easily prepared for transplantation by thawing and proliferating them when needed. (4) By performing HLA-ABC typing tests on isolated MSCs, it is possible to construct a cell bank of MSCs with low HLA-ABC expression. (5) As shown in Example 5 and Comparative Example 3 described below, the MSCs disclosed in the present application have the ability to secrete hepatocyte growth factor (HGF) extracellularly when cultured in a serum-free medium. MSCs have a wide range of therapeutic effects, including tissue repair and immunomodulatory effects, many of which are attributable to cytokines and growth factors secreted by MSCs (paracrine effect).
- HGF hepatocyte growth factor
- HGF is one of the most potent tissue regeneration-promoting factors, and has a variety of biological activities, including anti-fibrosis, anti-inflammatory, angiogenesis promotion, and cell proliferation promotion.
- the MSCs disclosed in the present application are HLA-ABC negative and HLA-G positive, and exhibit the unexpected effect of secreting HGF.
- the isolation and culture method according to an embodiment is a culture method for obtaining the above-mentioned MSCs from a placenta.
- the isolation and culture method includes an enzyme treatment step, a first culture step, and a second culture step.
- placental tissue collected from the placenta may be cut into pieces of, for example, 5 mm or less.
- enzymes used in the enzyme treatment step include, but are not limited to, collagenase, trypsin, papain, dispase, etc.
- placental tissues include placental tissues excluding the amnion, with the chorion and decidua on the decidual side being preferred. Examples of placenta include those from 16 weeks of pregnancy to full term.
- the first culture step is a step in which placental tissue-derived cells obtained by enzyme treatment are cultured in a serum-free medium.
- placental tissue-derived cells obtained by enzyme treatment are cultured in a serum-containing medium.
- the MSCs are HLA-ABC positive and HLA-G negative, the exact opposite of the MSC characteristics required for regenerative medicine.
- the isolation and culture method disclosed in this application is a new invention that discovers that cell culture in a serum-free medium can achieve the characteristics of low HLA-ABC expression (negative) and high HLA-G expression (positive).
- medium there are no particular limitations on the medium, as long as it does not contain serum. Any medium commonly used for cell culture can be used, as long as it does not contain serum. Examples of medium include, but are not limited to, DMEM liquid medium, DMEM/F12 liquid medium, and Neurobasal medium.
- MSCs are first selected from the cells cultured in the first culture step. Placental tissue contains many cells other than MSCs. Therefore, in the second culture step, the MSCs disclosed in the present application are first selected by excluding cells based on cell shape, HLA-ABC positive cells, etc. Then, as in the first culture step, the selected MSCs can be cultured using serum-free medium. Note that the medium used in the second culture step may have the same medium components as the first culture step, or may be different, as long as it is serum-free.
- the isolation and culture method according to the embodiment provides the following effects.
- MSCs that are HLA-ABC negative, HLA-G positive, and express MSC markers can be isolated and cultured from placental tissue using a simple method that uses a serum-free medium.
- the MSCs isolated in (1) above can be cultured and expanded in serum-free medium. Therefore, by expanding and culturing HLA-ABC-matched MSCs from the MSC bank, they can also be used as MSCs for allogeneic transplantation.
- the purification and concentration method is performed on MSCs cultured by the isolation and culture method according to the embodiment described above.
- MSCs By selecting MSCs during the second culture step, many of the cells cultured in the second culture step are considered to be MSCs, but it is possible that cells other than MSCs may be contaminated. It is also possible that MSCs may contain cells that do not possess the characteristics disclosed in the present application.
- MSCs with the characteristics disclosed in the present application can be concentrated.
- the purification and concentration method is not particularly limited as long as it can select MSCs with the characteristics disclosed in the present application from cells contained in a cell culture medium.
- an isolation method may be optionally carried out to isolate MSCs with desired characteristics from the concentrated MSC culture medium.
- MSCs with desired characteristics they can be used as parent lines for regenerative medicine, etc.
- the isolated MSCs may be subcultured as needed. When subcultured, a serum-free medium may be used, as in the first and second culture steps.
- the purification and concentration method disclosed in the present application has the following effects. (1) In actual clinical practice, it is expected that isolated and preserved MSCs will be cultured and used. By implementing the purification and concentration method, the probability that cells other than the MSCs disclosed in the present application will be contained in the culture medium will be reduced, thereby improving the convenience of isolating and preserving MSCs with desired characteristics. (2) During primary isolation and culture from placental tissue, maternal-derived, strongly elongated, thin, spindle-shaped HLA-ABC-positive MSCs are present. By carrying out a purification and concentration method using an HLA-ABC antibody at an early stage in the culture, maternal-derived, strongly HLA-ABC-positive MSCs can be removed.
- MSCs, isolation and culture methods, and purification and concentration methods are merely examples of each embodiment and are not limited to the described examples. Other components may be added or removed as long as they are within the scope of the technical concept disclosed in this application.
- MSCs having the characteristics disclosed in this application are isolated after the purification and concentration method is performed, but MSCs having the characteristics disclosed in this application may also be isolated from cells after the second culture step is performed.
- the bank includes two or more types of MSCs that are the MSCs according to the above-described embodiment, but that differ in at least one of the HLA typings (sometimes referred to as "HLA type"), i.e., MSCs that differ in the typing of the HLA-A locus, the HLA-B locus, and the HLA-DR locus, in other words, MSCs that differ in haplotypes, which are combinations of the HLA-A locus, the HLA-B locus, and the HLA-DR locus.
- HLA type sometimes referred to as "HLA type”
- the MSCs according to the embodiment are negative for HLA-ABC, which is involved in distinguishing between self and non-self, and therefore are unlikely to cause immune rejection.
- the MSCs according to the embodiment are negative for HLA-ABC, they do possess the genes that express HLA-A antigens, HLA-B antigens, and HLA-C antigens. Therefore, from the perspective of minimizing the risk of immune rejection as much as possible, it is preferable to provide patients with MSCs of the same HLA typing.
- the HLA type possessed by mammalian cells is determined by the combination of two inherited types, one type inherited from the father and one from the mother.
- a combination of the same HLA types is an HLA homozygote
- a combination of different HLA types is an HLA heterozygote.
- HLA-A There are six known types of human HLA, each with different functions and structures: HLA-A, HLA-B, and HLA-C, known as class I molecules, and HLA-DR, HLA-DQ, and HLA-DP, known as class II molecules.
- HLA-A HLA-A
- HLA-B HLA-B
- HLA-DR HLA-DR
- HLA-DQ HLA-DQ
- HLA-DP known as class II molecules
- HLA-A locus HLA-B locus
- HLA-DR locus HLA-DR locus
- allele groups of Japanese people (1) at the HLA-A locus, genotypes such as HLA-A*02, HLA-A*24, and HLA-A*01 are relatively common; (2) at the HLA-B locus, genotypes such as HLA-B*40, HLA-B*46, HLA-B*15, and HLA-B*51 are relatively common; and (3) at the HLA-DR locus, genotypes such as DRB1*04, DRB1*01, and DRB1*15 are relatively common.
- the MSCs contained in the bank be stored in association with at least information on the genotype of the HLA-A locus, information on the genotype of the HLA-B locus, information on the genotype of the HLA-DR locus, and the haplotype, which is the combination of the HLA-A locus, B locus, and DR locus. If at least one of the genotypes (typing) of the HLA-A locus, HLA-B locus, and HLA-DR locus is different, they can be said to be types of MSCs with different HLA types (different haplotypes).
- the bank contains at least two or more types of MSCs with different HLA types.
- the more types of MSCs with different HLA types contained in the bank the wider the range of patients to which they can be provided, so the types of MSCs contained in the bank may be 5 or more, 10 or more, 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, 100 or more, 200 or more, 300 or more, 400 or more, 500 or more, 600 or more, 700 or more, 800 or more, 900 or more, or 1000 or more.
- the bank it is desirable for the bank to contain MSCs with HLA types that match those prevalent in humans, as this will broaden the range of compatible patients.
- the website of the Japan Histocompatibility Society https://drive.google.com/file/d/1tn5Sgd2fkFf1bO0lnSBjmY4wiipZMgWD/view
- the most common subtypes are as follows: HLA-A: A*24:02, A*02:01, A*11:01, A*26:01, A*33:03, A*31:01.
- A*24:02 is most frequently found.
- HLA-B B*52:01, B*54:01, B*51:01, B*40:01, B*40:02, B*46:01, B*44:03, B*15:01, B*07:02. Among them, B*52:01 is most frequently found.
- HLA-DR DRB1*04:05, DRB1*09:01, DRB1*15:02, DRB1*08:03, DRB1*13:02, DRB1*14:03, DRB1*01:01. Among these, DRB1*04:05 is most frequently observed.
- the bank preferably contains MSCs with the following typing: -
- MSCs with the following typing: -
- A*24:02, A*02:01, A*11:01, A*26:01, A*33:03, and A*31:01 is included, and it is more preferable that A*24:02 is included.
- B*52:01 B*54:01, B*51:01, B*40:01, B*40:02, B*46:01, B*44:03, B*15:01, and B*07:02 is included, and it is more preferable that B*52:01 is included.
- DRB1*04:05 For typing of the HLA-DR locus, it is preferable that at least one selected from the group consisting of DRB1*04:05, DRB1*09:01, DRB1*15:02, DRB1*08:03, DRB1*13:02, DRB1*14:03, and DRB1*01:01 is included, and it is more preferable that DRB1*04:05 is included.
- At least one selected from the group consisting of A*24:02-B*52:01-DRB1*15:02, A*33:03-B*44:03-DRB1*13:02, A*24:02-B*07:02-DRB1*01:01, and A*24:02-B*54:01-DRB1*04:05 is included, and it is more preferable that A*24:02-B*52:01-DRB1*15:02 is included.
- At least one of the HLA types should include the above-mentioned HLA-A locus typing, HLA-B locus typing, HLA-DRB1 typing, and HLA haplotype.
- HLA-A locus typing is an example for Japanese people.
- HLA-B locus typing is an example for Japanese people.
- HLA-DRB1 typing is an example for Japanese people.
- the MSC information providing method is a method for providing MSC information contained in the MSC bank according to the embodiment described above.
- each MSC constituting an MSC bank is stored in association with typing information for at least the HLA-A locus, HLA-B locus, and HLA-DR locus of HLA typing, and optionally with a haplotype, which is a combination of the HLA-A locus, B locus, and DR locus.
- MSCs may also be stored in association with typing information for the HLA-C locus, DQ locus, and DP locus, as well as information such as cell type, race, and passage number.
- MSC information information associated with MSCs may be collectively referred to as "MSC information.”
- the MSC information provision method includes at least an HLA typing information input step for inputting the subject's HLA typing information, and an MSC information provision step.
- HLA typing information input step at least typing information for the subject's HLA-A locus, HLA-B locus, and HLA-DR locus may be input. If the subject is heterozygous, typing information for both alleles of the HLA-A locus, HLA-B locus, and HLA-DR locus may also be input.
- MSC information provision step if stored MSCs with a matching haplotype are included based on the input HLA typing information for the subject, MSC information with the matching haplotype may be provided.
- MSC information with two matching pieces of information from the typing information for the HLA-A locus, HLA-B locus, and HLA-DR locus, or MSC information with one matching piece of information may be provided. Furthermore, if the typing of the subject's HLA-A locus, HLA-B locus, and HLA-DR locus does not match at all with the stored MSCs, information should be provided to the effect that there are no stored MSCs that match at least one typing of the subject.
- MSCs according to the embodiment are cells that are unlikely to cause immune rejection.
- a discrimination step may be carried out to determine predetermined reference values and, based on the subject's HLA typing information, to identify MSCs that can be provided to the subject from among the MSCs stored in the bank.
- the discrimination step may identify the MSCs most suitable for the subject, or may identify multiple types of cells that can be provided to the subject.
- a provision step of the identified cells may be carried out.
- the haplotypes are a perfect match, MSCs that match the subject's haplotype may be provided without carrying out the discrimination step.
- the MSC information may be stored in a computer, and an HLA typing information input step, an MSC information provision step, and optionally an additional discrimination step may be carried out.
- the MSC bank and MSC information providing method according to the embodiment provide the following effects.
- MSCs that are less likely to cause immune rejection reactions can be provided to patients.
- MSCs according to the embodiment are cells that are unlikely to cause immune rejection. Taking this property and HLA typing into consideration, they can also be used in drug discovery research.
- the MSCs according to the embodiment are produced from placenta-derived cells, at least one of the HLA types of the mother or child of the placenta donor will be the same. Therefore, by linking the MSCs to donor information, they can be used favorably in the future when the donor mother or child requires treatment using MSCs.
- Example 1 MSCs were isolated and cultured from placental tissue by the following procedure. ⁇ First culture step> (1) Placental tissue (decidua including part of the chorion) was excised from the placenta at 38 weeks of gestation and cut into strips of 5 mm or less. (2) Enzyme treatment was carried out using collagenase (Sigma-Aldrich). (3) The enzyme-treated placental tissue was washed with phosphate-buffered saline (PBS). (4) Fibrin and other substances that were not dispersed by the enzyme treatment were removed using a cell strainer with a mesh size of 100 ⁇ m.
- PBS phosphate-buffered saline
- Cells were seeded in serum-free medium in a cell culture dish and cultured in a 5% carbon dioxide incubator at 37°C.
- the medium used was a mixture of equal volumes of serum-free DMEM/F12 medium (Cat No. 11320033) and Neurobasal medium (Cat No. 21103049). The medium was changed every 2 to 3 days.
- Figure 2A is a photograph of the dish five days after the start of cell culture. Thin, spindle-shaped cells, indicated by the arrowheads in Figure 2A, were observed. As will be described later, these cells were significantly elongated, thin, spindle-shaped, HLA-ABC-positive MSCs.
- CD105 mouse antibody (Themo Fisher Scientific) was diluted 100-fold with PBS containing 1% bovine serum albumin (BSA) and reacted at 37°C for 60 minutes. (6) Washed three times with PBS. (7) Anti-mouse Alexa Fluor 594-labeled secondary antibody (Thermo Fisher Scientific) was diluted 500-fold with 1% BSA-containing PBS, and HLA-ABC-FITC-labeled antibody (Beckman Coulter) was diluted 10-fold and reacted at 37°C for 60 minutes. (8) Washed three times with PBS.
- BSA bovine serum albumin
- ⁇ Second culture step> The MSCs of the present application were selected from the cells cultured in the first culture step, and the selected MSCs were cultured in the same procedure as in the ⁇ First culture step>.
- the MSCs disclosed in the present application were first selected based on cell shape. Specifically, from the cells in the dish obtained in the above-mentioned ⁇ First Culture Step>, cells with a spindle shape and elongated or expanded cytoplasm, as shown in Figure 2A, were removed using a scraper or chip, and the MSCs of the present application were selected on the plate. Note that the 14th day of culture shown below refers to the number of days from the enzyme treatment in the ⁇ First Culture Step>.
- CD105 mouse antibody (Themo Fisher Scientific) was diluted 100-fold with PBS containing 5% fetal bovine serum (FBS) and allowed to react at 4°C for 20 minutes.
- PBS was added, and the mixture was washed by centrifugation at 1,000 rpm for 5 minutes.
- Anti-mouse PE-labeled secondary antibody (BD Pharmingen) was diluted 200-fold with PBS containing 5% FBS, and HLA-ABC-FITC antibody (Beckman Coulter) was diluted 10-fold with PBS containing 5% FBS, and the mixture was incubated at 4°C for 20 minutes.
- PBS was added, and the mixture was washed by centrifugation at 1,000 rpm for 5 minutes.
- the aggregated cells were removed by passing through a cell strainer with a mesh size of 35 ⁇ m.
- Measurement was performed using a CytoFLEX flow cytometer.
- Figure 5 shows the results of the FCM analysis.
- the cells used in the FCM analysis will be explained with reference to Figure 3.
- the cells marked with arrowheads in the three photographs in Figure 3 are cells that are strongly positive for the MSC marker CD105 and positive for HLA-ABC.
- cells that are strongly positive for the MSC marker CD105 and positive for HLA-ABC are detected in the area surrounded by the dotted line in the graph for "HLA-ABC-FITC+CD105-PE" on the right side of Figure 5.
- the cells surrounded by the dotted circle in Figure 3 are a cell population that is positive for CD105 but negative for HLA-ABC.
- Figure 6A shows the results using an isotype control antibody
- Figure 6B shows the results using an HLA-G-APC-labeled antibody.
- Figure 6B shows the results using an HLA-G-APC-labeled antibody.
- Figure 6B shows the results using an HLA-G-APC-labeled antibody.
- Figure 6B shows the results using an HLA-G-APC-labeled antibody.
- FIG 6B shows that all cells cultured in serum-free medium (cells detected by FCM surrounded by a solid line in Figure 5, all HLA-ABC-positive and -negative cells, and all CD105-positive and -negative cells) were HLA-G-positive. Therefore, it was confirmed that the isolation and culture method disclosed in this application resulted in all MSCs being HLA-G-positive.
- HLA-ABC-negative and CD105-positive cells were purified from the cultured cells according to the following protocol.
- the cells detached from the cell culture dish were collected, and 10 mL of PBS was added thereto, followed by centrifugation at 1,000 rpm for 5 minutes to wash the cells.
- HLA-ABC-FITC labeled antibody (Beckman Coulter) was diluted 10-fold with PBS containing 5% FBS and reacted at 4°C for 20 minutes. (4) PBS was added, and the mixture was washed by centrifugation at 1,000 rpm for 5 minutes. (5) Anti-FITC microbeads (Miltenyi Biotec) were diluted 10-fold with PBS containing 5% FBS and reacted at 4°C for 20 minutes. (6) PBS was added, and the mixture was washed by centrifugation at 1,000 rpm for 5 minutes.
- the labeled cells were applied to a magnetic column (LD column, Miltenyi Biotec), and the fraction of cells that flowed out of the column (HLA-ABC-negative cells) was collected.
- PBS was added, and the mixture was washed by centrifugation at 1,000 rpm for 5 minutes.
- Anti-CD105 mouse antibody (Thermo Fisher Scientific) was diluted 100-fold and reacted at 4°C for 20 minutes.
- PBS was added and the mixture was washed by centrifugation at 1,000 rpm for 5 minutes.
- (11) Anti-mouse antibody microbeads (Miltenyi Biotec) were diluted 10-fold with PBS containing 5% FBS and reacted at 4°C for 20 minutes.
- Comparative Example 1 were immunostained using the same procedure as in [Immunostaining of cells on day 14 of culture (1)] of Example 1, except that in step (5) of [Immunostaining of cells on day 14 of culture (1)], a 100-fold dilution of CD90 mouse antibody (Themo Fisher Scientific) in PBS containing 1% bovine serum albumin (BSA) was used instead of the CD105 mouse antibody.
- CD90 mouse antibody Themo Fisher Scientific
- BSA bovine serum albumin
- the following considerations can be made depending on the presence or absence of serum in the medium when culturing MSCs.
- MSCs were cultured using a serum-containing medium, HLA-G-positive MSCs, which act on immune tolerance, were not obtained.
- MSCs were cultured using a serum-free medium, the MSCs were HLA-G-positive. Therefore, the isolation and culture method disclosed in the present application makes it possible to obtain HLA-G-positive MSCs, which could not be obtained by conventional methods.
- the proportion of HLA-ABC-positive cells significantly increased with increasing culture time.
- HLA-ABC-negative MSCs were isolated and preserved, their HLA-ABC characteristics may change from negative to positive during expansion culture or subculture for transplantation in a serum-containing medium.
- HLA-ABC did not change from negative to positive even when MSCs were subcultured in a serum-free medium. Therefore, the use of a serum-free medium allows the MSCs to maintain their HLA-ABC-negative and HLA-G-positive characteristics.
- Example 3 The cells obtained in Example 2 that were positive for MSC markers, negative for HLA-ABC, and positive for HLA-G were isolated, and the isolated MSCs were subcultured according to the following procedure. (1) Cells adhered to a cell culture dish were reacted with an enzyme (TrypLE TM Select Enzyme, Thermo Fisher Scientific) for 5 minutes in a 37°C, 5% carbon dioxide incubator. (2) The cells detached from the cell culture dish were collected, and 10 mL of PBS was added. (3) The mixture was washed by centrifugation at 1,000 rpm for 5 minutes. (4) The detached cells were seeded on a new culture dish and cultured using the same medium as in Example 1.
- an enzyme TrypLE TM Select Enzyme, Thermo Fisher Scientific
- FIG 11 shows a photograph of MSCs cultured for five passages.
- Figure 12 shows the results of FCM analysis performed using the same procedure as in Example 1.
- MSC markers CD105
- HLA-ABC HLA-ABC
- HLA-G HLA-G
- MSCs that are MSC marker positive, HLA-ABC negative, and HLA-G positive obtained by the isolation and culture method disclosed in this application can maintain the same characteristics even after passage when passaged in serum-free medium.
- Example 4 MSCs were produced from six placentas using the same procedure as in Example 2 described above. The produced MSCs were verified to be MSC cells using the same procedure as in Example 1, and were confirmed to be negative for HLA-ABC expression and positive for HLA-G expression. Next, the HLA-A locus, HLA-B locus, and HLA-DR locus of the six types of MSC cells produced were typed using the SSOP typing method (see "SSOP typing method for HLA-A, B, and DR in the Japanese population. MHC 8(3), 175-186, 2002. doi.org/10.12667/mhc.8.175").
- HLA-A locus subtypes, HLA-B locus subtypes, and HLA-DRB1 locus subtypes of the six types of MSCs were each included in the group of subtypes frequently found in Japanese people listed on the aforementioned website of the Japan Society for Histocompatibility Research (https://drive.google.com/file/d/1tn5Sgd2fkFf1bO0lnSBjmY4wiipZMgWD/view). Furthermore, of the six types of MSCs, (1) and (2) shared the same HLA-DRB1 subtype, DRB1*08:03, and (3) and (4) shared the same HLA-DRB1 subtype, DRB1*04:05, but the other typings were different.
- the MSCs disclosed in this application are negative for HLA-ABC expression and positive for HLA-G expression, and are therefore thought to be less likely to cause immune rejection when allografted. Furthermore, by creating a bank by storing the HLA typing information of the produced MSCs in association with typing information for at least the HLA-A locus, HLA-B locus, and HLA-DR locus, it is possible to provide MSCs suitable for patients based on their HLA typing information. Information identifying each MSC contained in the bank and the HLA typing information of the MSCs can be stored, for example, in a computer, and a program can be stored that can identify the iMSCs to be provided by inputting the patient's HLA typing information.
- Example 5 The amount of HGF secreted by MSCs was measured according to the procedure described below. (1) Cryopreserved MSCs (prepared in Example 2) were thawed, added to 9 mL of medium (serum-free medium used in Example 1), and centrifuged at 800 G for 3 minutes. (2) After aspirating the supernatant, 10 mL of medium was added, and the number of viable cells was counted using trypan blue. (3) The cells were dispensed into a 6-well multiplate so that the number of cells in each well was 5 x 10 4 . (4) The cells were incubated at 37°C, 5% CO 2 , and 100% humidified. (5) After 3 days of culture, the medium was changed. (6) On the 7th day of culture, the cell supernatant (hereinafter referred to as "sample”) was collected and stored frozen at -80°C.
- HGF contained in the cell supernatant was measured according to the following procedure. The following measurement was performed using the AuthentiKine TM HGF ELISA Kit. All reagents except for the sample were included in the kit. (7) 100 ⁇ L each of the standard and the sample was dispensed into appropriate wells. (8) The plate was incubated at 37°C for 2 hours. (9) Wash four times with 1x Wash Buffer. (10) 100 ⁇ L of 1 ⁇ Detection antibody, HRP-conjugated, was added to each well, and the plate was incubated at 37° C. for 40 minutes. (11) Wash four times with 1x Wash Buffer.
- the HGF concentration in the cell supernatant was 15.5 ng/mL.
- the background value measured using a standard sample not containing MSCs was 0.6 ng/mL.
- Example 5 The results of Example 5 and Comparative Example 3 confirmed that the MSCs disclosed in this application secrete the growth factor HGF when cultured in serum-free medium.
- the value in Example 5 is approximately 26 times that of Comparative Example 3. Therefore, culturing MSCs in serum-free medium as disclosed in the present application can be applied to a method for producing HGF with high efficiency.
- the production method may include a culture step in which MSCs are cultured in serum-free medium and an HGF purification step in which HGF contained in the cell supernatant is purified.
- HGF purification step There are no particular limitations on the HGF purification step, as long as it can purify HGF contained in the cell supernatant. It is sufficient that HGF contained in the cell supernatant can be purified by using known means such as, but not limited to, ion exchange chromatography, affinity chromatography, gel filtration chromatography, etc., as appropriate (combined as necessary).
- the isolation and culture method disclosed in the present application allows for the production of MSCs that are MSC marker positive, HLA-ABC negative, and HLA-G positive. Furthermore, the resulting MSCs maintain their characteristics even after subculture, making them useful in the medical industry.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026531671A JPWO2026029097A1 (cg-RX-API-DMAC7.html) | 2024-07-30 | 2025-07-30 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024123670 | 2024-07-30 | ||
| JP2024-123670 | 2024-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2026029097A1 true WO2026029097A1 (ja) | 2026-02-05 |
Family
ID=98606712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2025/026989 Pending WO2026029097A1 (ja) | 2024-07-30 | 2025-07-30 | 新規幹細胞の分離培養方法、単離された新規幹細胞、間葉系幹細胞バンク、および、間葉系幹細胞情報提供方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2026029097A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2026029097A1 (cg-RX-API-DMAC7.html) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009521929A (ja) * | 2005-12-29 | 2009-06-11 | アントフロゲネシス コーポレーション | 胎盤幹細胞集団 |
| US20150203820A1 (en) * | 2012-07-12 | 2015-07-23 | Imstem Biotechnology, Inc. | Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| US20160184364A1 (en) * | 2013-08-14 | 2016-06-30 | Stempeutics Research Pvt. Ltd. | Management of osteoarthritis using pooled allogeneic mesenchymal stem cells |
| US20210038651A1 (en) * | 2018-03-06 | 2021-02-11 | Orig3N, Inc. | Ipsc-derived cell compositions, and related systems and methods for cartilage repair |
| US20210213066A1 (en) * | 2018-05-18 | 2021-07-15 | Children's National Medical Center | Improved cell therapy compositions for hematopoietic stem cell transplant patients |
| WO2021201286A1 (ja) * | 2020-04-02 | 2021-10-07 | 国立大学法人東北大学 | ハイポテンシャル多能性幹細胞 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101330935B (zh) * | 2005-10-21 | 2013-11-13 | 细胞研究私人有限公司 | 自脐带羊膜分离和培养干/祖细胞及其分化的细胞的应用 |
| CA2734237C (en) * | 2008-08-20 | 2019-07-02 | Anthrogenesis Corporation | Treatment of stroke using isolated placental cells |
| JP7126703B2 (ja) * | 2016-05-24 | 2022-08-29 | 国立大学法人 東京大学 | 臍帯由来細胞を含む脳障害の治療剤 |
| CN116769707B (zh) * | 2023-08-18 | 2023-11-10 | 北京葆来生物科技有限公司 | 一种增强间充质干细胞表达肝生长因子的无血清培养基及增强表达hgf的培养方法 |
-
2025
- 2025-07-30 JP JP2026531671A patent/JPWO2026029097A1/ja active Pending
- 2025-07-30 WO PCT/JP2025/026989 patent/WO2026029097A1/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009521929A (ja) * | 2005-12-29 | 2009-06-11 | アントフロゲネシス コーポレーション | 胎盤幹細胞集団 |
| US20150203820A1 (en) * | 2012-07-12 | 2015-07-23 | Imstem Biotechnology, Inc. | Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| US20160184364A1 (en) * | 2013-08-14 | 2016-06-30 | Stempeutics Research Pvt. Ltd. | Management of osteoarthritis using pooled allogeneic mesenchymal stem cells |
| US20210038651A1 (en) * | 2018-03-06 | 2021-02-11 | Orig3N, Inc. | Ipsc-derived cell compositions, and related systems and methods for cartilage repair |
| US20210213066A1 (en) * | 2018-05-18 | 2021-07-15 | Children's National Medical Center | Improved cell therapy compositions for hematopoietic stem cell transplant patients |
| WO2021201286A1 (ja) * | 2020-04-02 | 2021-10-07 | 国立大学法人東北大学 | ハイポテンシャル多能性幹細胞 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2026029097A1 (cg-RX-API-DMAC7.html) | 2026-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bohlen et al. | Isolation and culture of microglia | |
| Kim et al. | Comparative analysis of MSC-derived exosomes depending on cell culture media for regenerative bioactivity | |
| Yi et al. | Comparative separation methods and biological characteristics of human placental and umbilical cord mesenchymal stem cells in serum-free culture conditions | |
| US7101710B2 (en) | Two-stage culture protocol for isolating mesenchymal stem cells from amniotic fluid | |
| Rossi et al. | Isolation and in vitro characterization of bovine amniotic fluid derived stem cells at different trimesters of pregnancy | |
| Suszynska et al. | The proper criteria for identification and sorting of very small embryonic-like stem cells, and some nomenclature issues | |
| Dissanayake et al. | Oviduct as a sensor of embryo quality: deciphering the extracellular vesicle (EV)-mediated embryo-maternal dialogue | |
| Araújo et al. | Isolation of human mesenchymal stem cells from amnion, chorion, placental decidua and umbilical cord: comparison of four enzymatic protocols | |
| Iacono et al. | Could fetal fluid and membranes be an alternative source for mesenchymal stem cells (MSCs) in the feline species? A preliminary study | |
| Conboy et al. | Immuno-analysis and FACS sorting of adult muscle fiber-associated stem/precursor cells | |
| Cardoso et al. | Characterization of teratogenic potential and gene expression in canine and feline amniotic membrane‐derived stem cells | |
| Zuba‐Surma et al. | Overview of very small embryonic‐like stem cells (VSELs) and methodology of their identification and isolation by flow cytometric methods | |
| Kamm et al. | Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression | |
| KR20050086780A (ko) | 세포요법제, 세포요법제 단위 및 이를 이용한 치료방법 | |
| JP2021507711A (ja) | 間葉系間質細胞及び臍帯から間葉系間質細胞を得るための方法 | |
| KR100818214B1 (ko) | 인간 태반조직의 양막 또는 탈락막 유래 다분화능 줄기세포및 그 제조방법 | |
| Garcia et al. | Human satellite cell isolation and xenotransplantation | |
| Safitri et al. | Honeybee product therapeutic as stem cells homing for ovary failure | |
| JP6301263B2 (ja) | ヒト臍帯組織由来細胞の検出 | |
| US20150216911A1 (en) | Multipotent Prenatal Stem Cells | |
| Czétány et al. | An alternative application of magnetic-activated cell sorting: CD45 and CD235a based purification of semen and testicular tissue samples | |
| US20160158292A1 (en) | Method and apparatus for recovery of umbilical cord tissue derived regenerative cells and uses thereof | |
| Kulka et al. | Isolation of tissue mast cells | |
| Davydova et al. | Cell phenotypes in human amniotic fluid | |
| Uçkan-Çetinkaya et al. | Induced pluripotent stem cells in pediatric research and clinical translation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 25848149 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2026531671 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2026531671 Country of ref document: JP |